New Zealand markets close in 3 hours 33 minutes

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
3.9400+0.2200 (+5.91%)
At close: 03:59PM EDT
Full screen
Previous close3.7200
Open3.7600
Bid3.9000 x N/A
Ask3.9500 x N/A
Day's range3.7600 - 3.9800
52-week range3.4400 - 9.1000
Volume21,500
Avg. volume67,308
Market cap140.353M
Beta (5Y monthly)1.13
PE ratio (TTM)N/A
EPS (TTM)-1.1700
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.45
  • PR Newswire

    Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program. The Clinical Advisory Board is comprised of Dr. Evan Dellon (Chairman), Dr. Stephen Attwood, Dr. Albert Bredenoord, Dr. Donna Griebel, Dr. Ikuo Hirano

  • PR Newswire

    Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024. The meeting is being held in Vienna, Austria from April 18-21, 2024.

  • PR Newswire

    Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that senior management will deliver a corporate presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto.